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Abstract 
Human breast cancer represents a group of highly heterogeneous lesions consisting of about 
20 morphologically distinct subtypes with substantially different molecular and/or biochemical 
signatures, clinical courses, and prognoses. This study analyzed the possible correlation 
between the morphological presentations of breast cancer and two hypothesized models of 
carcinogenesis, in order to identify the intrinsic mechanism(s) and clinical implications of 
breast cancer heterogeneity.  
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1. Breast cancer heterogeneity 
Human breast cancer represents a group of 
highly heterogeneous lesions consisting of about 20 
morphologically distinct subtypes [1-2] (Table 1; Fig 
1). 
Table 1. Morphological classification of human breast 
cancer  
# Morphological  classification #  Morphological  classifica-
tion 
1 Inflammatory 11  Clear  cell 
2 Pregnancy-associated 12  Medullary 
3 Comedo  13  Secretory 
4 Micropapillary 14  Signet ring cell 
5 Papillary 15  Mucinous 
6 Cribriform  16  Tubular 
7 Solid  17  Lobular  neoplasia 
8 Clinging  18  Mixed cell types 
9 Spindle cell  19  Apocrine 
10 Neuroendocrine  20 Malignant  myoepitheli-
oma 
 
 
Among these subtypes, inflammatory and 
pregnancy-associated breast cancers have the most 
aggressive clinical course, in which many tumors had 
undergone extensive invasion or metastasis at the 
diagnosis [3-6]. In sharp contrast, small tubular and 
mucinous cancers have the most indolent clinical 
course, in which most  pre-invasive cancers do not 
progress during patients’ lifetime [1,2].  
Breast cancer also has a highly variable profile of 
molecular and immunohistochemical signatures, and 
could be roughly divided into 5-categories based on 
their expression of estrogen receptor (ER), progeste-
rone receptor (ER), human epidermal growth factor 
receptor-1 and 2 (HER-1 and 2), and cytokeratins 5/6 
(CK 5/6) [7-9] (Table 2).  
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Table 2. Molecular and immunohistochemical classification of human breast cancer 
Category   Signature   Treatment 
Luminal A  ER(+) and/or PR(+); HER-2(-)  Endocrine RX; Tamoxifen 
Luminal B  ER(+) and/or PR(+); HER-2(+)  Tratuzumab; Tamoxifen 
Basal-like ER(-); PR(-); HER-2(-);CK5/6(+); HER-1(+)  Neoadjuvant RX 
HER-2(+)/ER(-) HER-2(+); ER(-); PR(-)  Neoadjuvant RX 
Normal breast-like  All markers(-)   
 
 
 
 
Fig 1. Breast tumor morphological heterogeneity. Sections from 4-different human breast tumors were stained with H&E. 
Note that although all are ductal carcinoma in situ, each has its unique morphological features. 
 
2. Mechanisms of heterogeneity  
The mechanism(s) accounting for breast cancer 
heterogeneity remains elusive. However, two pre-
viously introduced theories, cancer stem cells and 
clonal evolution, appear to have provided some rea-
sonable explanations. The theory of cancer stem cell 
was originated by Cohnheim in 1875 [10]. The main 
concept and major steps are depicted in Fig 2.  
The theory of clonal evolution was introduced 
by Nowell in 1976 [11]. The main concept and major 
steps are depicted in Fig 3.  
 
Fig 2. The theory of cancer stem cells for breast cancer heterogeneity  
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1.  A number of external or internal   
insults, such as radiation, injury, 
or carcinogens, may result in 
genetic damages in the stem cells.
2.  Each damaged stem cell gives  
rise to a morphologically distinct    
type of tumor.
3.  All the cells within a given tumor 
share the same profile at 
different stages of progression
4.   Different tumors from different 
stem cells have different genetic
and biochemical profilesJournal of Cancer 2010, 1 
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Fig 3. The theory of clonal evolution of breast cancer heterogeneity  
 
These theories share a number of similarities, 
including: (1) both believe that cancers are originated 
from cancer stem cells;(2) both believe that specific 
genetic or biochemical abnormalities are needed for 
carcinogenesis, and (3) both believe that the tumor 
microenvironment substantially influence the 
processes of carcinogenesis and tumor progression. 
However, these theories differ fundamentally in the 
main concept. The cancer stem cell theory believes 
that different tumors result from different stem cells, 
and that all cells within a given tumor could progress 
to a higher degree of malignancy. In sharp contrast, 
the clonal evolution theory believes that different 
tumors are originated from evolution of a single stem 
cell and that only the more aggressive clone 
progresses. 
3. Proofs for each theory 
The cancer stem cell theory is supported by sev-
eral lines of evidence, including: 
A. Different lobules have different morphological 
and immunohistochemical profiles 
In H&E stained sections, all or nearly all lobules 
are clearly segregated by inter-lobular stromal tissues 
with a distinct boundary. All epithelial cells within a 
given lobule are morphologically and immunohisto-
chemically similar, but they often differ substantially 
from cells in adjacent lobules. As shown in Fig 4, all 
cells within a large lobule in the center of the section 
are devoid of cytokeratin -19 (CK-19), whereas all or 
nearly all cells within adjacent lobules are CK-19 pos-
itive. 
B. Malignancy-associated alterations in isolated 
lobules  
Our previous studies detected elevated cytop-
lasmic expression of HER-2 in some normal appearing 
lobules [12]. As shown in Fig 5, these lobules (circles) 
are segregated from other lobules with a distinct 
boundary. Most cells within these lobules show 
strong cytoplasm expression of HER-2, whereas all or 
nearly all cells in adjacent lobules (squares) are devoid 
of HER-2 expression.  
Together, these findings suggest that different 
lobules are likely to arise from different stem cells, 
which constitutes the molecular base of heterogeneity 
for tumors subsequently derived from these lobules. 
This speculation is in total agreement with our pre-
vious findings in surgically operated rat submandi-
bular glands with an integrated immunohistichemical 
and autoradiographical approach, which revealed the 
formation of morphologically and immunohisto-
chemically unique new lobules within the residual 
gland by stem cells [13,14] (Fig 6).  
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stem cell 1.  A number of external or internal   
insults, such as radiation, injury, 
or carcinogens, may result in 
genetic damages in stem cells.
2.  A genetically damaged stem 
cell gives rise to a morphological  
distinct type of tumor.
3.  New cell clones constantly   
emerge from the same tumor
4.  Only the more aggressive ones   
with growth advantages progress, 
and from which, new clones   
emergeJournal of Cancer 2010, 1 
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Fig 4. Morphologically and immunohistochemically different lobules. A human breast tissue section was double immu-
nostained for smooth muscle actin (red) and CK-19 (brown). Circle identifies a lobule consisting of all CK-19 negative cells. 
Arrows identify CK-19 positive cells in adjacent lobules.  
 
 
Fig 5. Aberrant HER-2 expression in isolated normal appearing lobules. A human breast tissue section was double im-
munostained for smooth muscle actin (red) and HER-2 (black).  Journal of Cancer 2010, 1 
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Fig 6. Formation of unique new lobules within residual submandibular glands (SMG) by stem cells after surgical operation. 
Rat SMG removed 4-weeks after partial removal of the gland and TdR injection was used for immunohistochemistry & 
autoradiography. Circles identify newly formed lobules. Squares identify pre-existing lobules within the residual gland.  
The clonal evolution theory is also supported by 
several lines of evidence, including: 
A. ER-negative cell clusters “budding” from ER- 
positive ductal tumor cores. 
With a double immunohistochemical method, 
our previous studies revealed that a subset of 
ER-positive pre-invasive breast tumors harbored focal 
disruptions in 
their myoepi-
thelial cell 
layers. Over 
86% of these 
disruptions 
were overlaid 
by 
ER-negative cell clusters, but adjacent cells within the 
tumor core were ER-positive [15-18] (Fig 7). The size 
of ER-negative cell clusters appeared to increase with 
tumor progression. The tumor cells at the tip of these 
clusters gradually regained ER expression, but the 
cells near the tumor core were consistently devoid of 
ER expression (Fig 7b).  
 
 
Fig 7. ER(-) cell 
“budding” from 
ER(+) tumors. 
Human breast 
tissue sections 
were double 
immunostained 
for SMA (red) 
and ER (brown). 
Circles identify 
ER(-) cells near 
the tumor cores. Squares identify ER(+) cells at the tip of an 
ER(-) cell cluster. Arrow identifies a ER(+) cell between the 
base and the tip of a ER(-) cell cluster.  
   
ABJournal of Cancer 2010, 1 
 
http://www.jcancer.org 
11
B. “Budding” cell clusters and cells within tumor 
cores have a different molecular profile  
Molecular analyses with microdissected “bud-
ding” cells and adjacent cells within the tumor core 
detected a markedly different rate of LOH and ex-
pression of invasion-related genes [17] (Fig 8).  
4. Scientific and clinical implications 
Together, these findings suggest that both the 
cancer stem cell and clonal evolution could contribute 
to breast cancer heterogeneity, in which, the cancer 
stem cell is more likely to contribute to lobular cancer 
heterogeneity, while the clonal evolution is more 
likely to contribute to ductal cancer heterogeneity. 
  If further validated, these theories and findings 
could have significant scientific and clinical implica-
tions. Scientifically, in order to identify the trigger 
factor(s) shared by all or most subtypes of breast 
cancers for their invasion and metastasis, a novel tar-
get highly representative to all or most subtypes is 
apparently needed to be elucidated, so that further 
studies could be carried out in comparable tissue 
samples. Clinically, breast cancers derived from clonal 
evolution are very likely to be more problematic for 
early detection and intervention for two main reasons:  
A. Tumor invasion or metastasis may occur at 
normal or hyperplastic stages 
Our recent studies in nearly 1,000 cases of breast 
cancer have consistently shown that a subset of nor-
mal or hyperplastic breast duct clusters show malig-
nancy-associated changes, including focal disruptions 
in the surrounding myoepithelial cell layer and 
basement membrane, expression of p53 and HER-2, 
morphological signs of stromal and vascular invasion 
[19,20] (Fig 9). These duct clusters may progress di-
rectly into invasive or metastatic lesions.  
 
Fig 8. Differential expression of invasion-related genes between “budding” cells (circle) and cells within the tumor core 
(yellow square). Black squares identify differentially expressed genes between these two cell types of the same tumor.  
 
Fig 9. Normal appearing breast ducts with malignancy-associated changes. A section of human breast tumor tissues was 
double immunostained with a specific marker for myoepithelial cells (red) and ER (brown). Circle identifies budding ER(-) 
cells from a ER(+) normal appearing duct. Square identifies ER(-) cells within a small dilated vein.   
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B. ER-negative cell clusters may represent 
“seeds” for drug resistant and recurrent tumors  
Our recent studies have consistently shown that 
ER-negative cells overlying focally disrupted myoe-
pithelial cell layers are generally arranged as tongue- 
or finger-like projections invading the adjacent 
stromal tissue or vascular structures [15-18]. The size 
of these ER-negative cell clusters increased with tu-
mor progression, and an increasing number of 
ER-positive cells were seen at the tips of these projec-
tions. In contrast, the ER-negative cell clusters over-
lying focally disrupted myoepithelial cell layers near 
the tumor core were consistently devoid of ER ex-
pression (Fig 10). These findings suggest these 
ER-negative cell clusters are likely to represent a 
population of a more aggressive cell clone that is un-
der clonal evolution. Since these “budding” cells near 
the tumor core are consistently devoid of ER expres-
sion, they are unlikely to respond to tamoxifen and 
other hormonal-based therapies, representing “seeds” 
for drug resistant and recurrent breast tumors.  
 
 
Fig 10. Changeable ER expression in “budding” cells overlying focally disrupted myoepithelial cell layers. Section was dobble 
immunostained with specific markers to the myoepithelial cell layer (red) and ER (brown). Circle identifies ER-negative cell 
cluster overlying focally disrupted myoepithelial cell layer. Square identifies ER-negative cell cluster derived ER-positive cells 
within the stromal tissue.  
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